Progress in Vaccination Against Cancer (PIVAC) aims to bring together translational and clinical oncologists and immunologists dealing with active vaccination against cancer for three days of presentations on the most recent advances in the field. The meeting provides an up-to-date overview of many aspects of tumour immunology. Thanks to its friendly atmosphere and the limited number of participants, PIVAC cultivates lively and fruitful discussions, promotes interactions between participants, speakers and companies attending the conference and encourages the emergence of new partnerships.
Background
The exploitation of the immune system to fight tumours has huge potential, but it still represents a challenge to be overcome. New information has been recently gathered on: the role of the tumour microenvironment as a major factor in determining the immunotherapy outcome; the exploitation of comparative oncology to predict immunotherapy effectiveness; and the potentialities of various vaccination strategies. Moreover, initial positive clinical results are becoming apparent. These new acquisitions will be the focus of PIVAC-16.
Who should attend?
PIVAC is dedicated to scientists working on active immunization against cancer, both in prevention and therapy, at the pre-clinical and/or clinical level. PIVAC is also an ideal environment to stimulate the interest of students and young researchers who approach this field of research.
Topics to be covered in the conference include:
- Nucleic acid vaccines
- Plant derived vaccines
- Viral targeting of cancer
- Phosphopetide targeting
- Immunological adjuvancy through PI3K inhibition and chemotherapy
- Immunostimulatory antibodies
- Role of B-cells in solid cancers
We look forward to welcoming you to historic Winchester for this exciting conference!
